Ken Griffin Ascendis Pharma A/S Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $2.15 Million - $2.92 Million	19,000 Added 246.75%	26,700 $3.99 Million
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $24,214 - $30,733	-200 Reduced 2.53%	7,700 $1.05 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $345,660 - $446,320	2,800 Added 54.9%	7,900 $1.19 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $792,120 - $1.17 Million	-9,200 Reduced 64.34%	5,100 $642,000
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $354,650 - $426,277	-4,100 Reduced 22.28%	14,300 $1.34 Million
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $580,668 - $812,072	8,300 Added 82.18%	18,400 $1.64 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $2.29 Million - $2.76 Million	-21,800 Reduced 68.34%	10,100 $1.08 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $2.43 Million - $3.22 Million	24,400 Added 325.33%	31,900 $3.9 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $478,971 - $628,311	-5,700 Reduced 43.18%	7,500 $774,000

243

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.24B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.